"uuid:ID","versionIdentifier","id","rationale","instanceType"
"c1b1d0f8-2975-4585-aa42-0872f66a25bb","2","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
